Here we are! #Under40 jessica gill Lorenzo Cani

List of top 10 plasma cell dyscrasia #ASH23 abstracts. List may reflect positive/negative studies, but all have influenced thinking. I will summarize each study with teaching point. If you are wondering if there are any practice changing myeloma studies- IMO answer is NO. 🧵

Just out: My 2024 Update on diagnosis, risk stratification, and treatment of myeloma. #AJH Mayo Clinic Comprehensive Cancer Center 10 Tables; Algorithms Includes current data including trials published this month! #ASCO24 onlinelibrary.wiley.com/doi/10.1002/aj…

It’s out! After 14+ long years of enrollment, analysis and follow up the CoMMpass trial is published in full format nam11.safelinks.protection.outlook.com/?url=https%3A%…. Thanks to J Keats, all the investigators, Multiple Myeloma RF and to the patients who were part of this landmark study.

Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population ow.ly/lLTV50SYJJR #clinicaltrialsandobservations #lymphoidneoplasia

Outcomes with quadruplet induction and risk adapted maintenance in myeloma. Major progress. Dr. Nisha Joseph, Ajay Nooka, MD, MPH Sagar Lonial MD et al Winship Cancer Institute of Emory University Blood Cancer Journal nature.com/articles/s4140…

Looking forward to my first #ASH2024 and to share the results of Winship Cancer Institute of Emory University about risk of infections in MM pts treated with BsAbs. Stay tuned!

That’s a point!

Here we are #ASH24

Presented at #ASH24: Among patients with smoldering multiple myeloma at a high risk for progression, progression-free survival at 5 years was 63.1% with daratumumab monotherapy, as compared with 40.8% with active monitoring. Full AQUILA trial results: nej.md/3Zh3pOJ

Our review on the current state of BCL2 inhibitors for myeloma and amyloidosis is now online. Great job! Jonathan Kaufman, MD Vikas Gupta onlinelibrary.wiley.com/share/author/Z…

Thrilled to share our article out on Clinical Lymphoma, Myeloma & Leukemia, which explores the current use of FISH in the management of multiple myeloma in Italy. Mattia D’Agostino great work! clinical-lymphoma-myeloma-leukemia.com/article/S2152-…

Now out as early view in Haematologica results from Ist part of REAL trial doi.org/10.3324/haemat…. In elderly NDMM pts, VMP shows better OS then Rd (especially in HR CG pts). Preliminary data on whether this advantage is confirmed with the addition daratumumab expected soon.

Finally out in The Lancet Haematology the EMN-20 trial. KRD with weekly K and MRD driven approach for K discontinuation led to a 60% MRD negativity rate at 2 yrs in NTE NDMM fit and intermediate-fit pts. Take a look- thelancet.com/journals/lanha…

Debulking before BsAb to⬆️outcomes for #RRMM ➡️n=44,50% EMD,HRCG,⬆️BM Dx ➡️C/w historical cohorts, ⬆️ORR and PFS in EMD ➡️Need to define optimal debulking (⬇️M-Prt, sFLC, PET SUV) and c/w matched control of no prior debulking 10.1038/s41408-025-01365-y #MMSM Blood Cancer Journal